CN105960397B - Cgrp-活性化合物的片剂制剂 - Google Patents

Cgrp-活性化合物的片剂制剂 Download PDF

Info

Publication number
CN105960397B
CN105960397B CN201580006288.6A CN201580006288A CN105960397B CN 105960397 B CN105960397 B CN 105960397B CN 201580006288 A CN201580006288 A CN 201580006288A CN 105960397 B CN105960397 B CN 105960397B
Authority
CN
China
Prior art keywords
tablet
formula
compound
extrudate
formulation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201580006288.6A
Other languages
English (en)
Chinese (zh)
Other versions
CN105960397A (zh
Inventor
M·A·约翰逊
L·R·阿兰
W·M·艾克霍夫
C·B·艾克达
C·D·布朗
小弗朗西斯·J·弗拉纳根
R·诺夫辛格
M·马罗塔
L·勒普顿
P·B·帕特尔
席晗宓
W·许
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Sharp and Dohme BV
Original Assignee
Merck Sharp and Dohme LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=53778348&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN105960397(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Merck Sharp and Dohme LLC filed Critical Merck Sharp and Dohme LLC
Priority to CN202010812438.5A priority Critical patent/CN112022818A/zh
Publication of CN105960397A publication Critical patent/CN105960397A/zh
Application granted granted Critical
Publication of CN105960397B publication Critical patent/CN105960397B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Inorganic Chemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Cephalosporin Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
CN201580006288.6A 2014-02-05 2015-01-30 Cgrp-活性化合物的片剂制剂 Active CN105960397B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202010812438.5A CN112022818A (zh) 2014-02-05 2015-01-30 Cgrp-活性化合物的片剂制剂

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201461936019P 2014-02-05 2014-02-05
US61/936,019 2014-02-05
US201462087366P 2014-12-04 2014-12-04
US62/087,366 2014-12-04
PCT/US2015/013672 WO2015119848A1 (en) 2014-02-05 2015-01-30 Tablet formulation for cgrp-active compounds

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202010812438.5A Division CN112022818A (zh) 2014-02-05 2015-01-30 Cgrp-活性化合物的片剂制剂

Publications (2)

Publication Number Publication Date
CN105960397A CN105960397A (zh) 2016-09-21
CN105960397B true CN105960397B (zh) 2020-09-04

Family

ID=53778348

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201580006288.6A Active CN105960397B (zh) 2014-02-05 2015-01-30 Cgrp-活性化合物的片剂制剂
CN202010812438.5A Pending CN112022818A (zh) 2014-02-05 2015-01-30 Cgrp-活性化合物的片剂制剂

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202010812438.5A Pending CN112022818A (zh) 2014-02-05 2015-01-30 Cgrp-活性化合物的片剂制剂

Country Status (13)

Country Link
US (4) US10117836B2 (enExample)
EP (1) EP3102564A4 (enExample)
JP (2) JP6491669B2 (enExample)
KR (3) KR20220136460A (enExample)
CN (2) CN105960397B (enExample)
AU (5) AU2015214502B2 (enExample)
CA (1) CA2937315A1 (enExample)
HK (1) HK1232218A1 (enExample)
IL (1) IL246828B (enExample)
MX (2) MX383378B (enExample)
RU (2) RU2019123406A (enExample)
SA (1) SA516371613B1 (enExample)
WO (1) WO2015119848A1 (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI522355B (zh) * 2010-11-12 2016-02-21 默沙東藥廠 六氫吡啶酮甲醯胺氮雜茚滿ｃｇｒｐ受體拮抗劑
KR20220136460A (ko) 2014-02-05 2022-10-07 머크 샤프 앤드 돔 엘엘씨 Cgrp-활성 화합물에 대한 정제 제제
US12168004B2 (en) 2014-02-05 2024-12-17 Merck Sharp & Dohme Llc Treatment of migraine
CN105126111A (zh) * 2015-09-30 2015-12-09 清华大学 提高索拉非尼生物利用度的制剂
ES2968399T3 (es) 2017-03-30 2024-05-09 Merck Patent Gmbh Formulación farmacéutica
DK4088720T3 (da) * 2018-03-25 2025-09-29 Pfizer Ireland Pharmaceuticals Unlimited Company Rimegepant til cgrp-relaterede lidelser
US12383545B1 (en) 2018-06-08 2025-08-12 Allergan Pharmaceuticals International Limited Treatment of migraine
RU2755571C1 (ru) * 2020-06-09 2021-09-17 Сергей Геннадьевич Каплунов Способ изготовления гравюры на металле
AU2021319090A1 (en) 2020-07-29 2023-03-02 Allergan Pharmaceuticals International Limited Treatment of migraine
IL302948A (en) * 2020-11-19 2023-07-01 Pfizer Ireland Pharmaceuticals Compositions for improved delivery of cgrp inhibitors
CN116456981A (zh) * 2020-11-19 2023-07-18 辉瑞爱尔兰制药公司 用于改善的grp抑制剂递送的组合物
WO2022140537A1 (en) 2020-12-22 2022-06-30 Allergan Pharmaceuticals International Limited Treatment of migraine
US20240116913A1 (en) * 2021-02-02 2024-04-11 Idorsia Pharmaceuticals Ltd A crystalline form of (4-methyl-2-[1,2,3]triazol-2-yl-phenyl)-[(r)-3-(3-[1,2,3]triazol-2-yl-benzyl)-morpholin-4-yl]-methanone
WO2023049920A1 (en) 2021-09-27 2023-03-30 Allergan Pharmaceuticals International Limited Combination comprising atogepant for treating migraine

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040076668A1 (en) * 2002-07-03 2004-04-22 Pfizer Inc. Controlled-release pharmaceutical formulations
CN101378731A (zh) * 2006-02-09 2009-03-04 默克公司 Cetp抑制剂的聚合物制剂
CN103328478A (zh) * 2010-11-12 2013-09-25 默沙东公司 哌啶酮羧酰胺氮杂茚满cgrp受体拮抗剂

Family Cites Families (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4166452A (en) 1976-05-03 1979-09-04 Generales Constantine D J Jr Apparatus for testing human responses to stimuli
US4256108A (en) 1977-04-07 1981-03-17 Alza Corporation Microporous-semipermeable laminated osmotic system
US4265874A (en) 1980-04-25 1981-05-05 Alza Corporation Method of delivering drug with aid of effervescent activity generated in environment of use
DE3612212A1 (de) 1986-04-11 1987-10-15 Basf Ag Verfahren zur herstellung von festen pharmazeutischen formen
TW486370B (en) 1996-12-25 2002-05-11 Yamanouchi Pharma Co Ltd Rapidly disintegrable pharmaceutical composition
US6103260A (en) * 1997-07-17 2000-08-15 Mcneil-Ppc, Inc. Simethicone/anhydrous calcium phosphate compositions
US7288559B2 (en) 2003-03-14 2007-10-30 Merck + Co, Inc. Carboxamide spirohydantoin CGRP receptor antagonists
JP4584914B2 (ja) 2003-03-14 2010-11-24 メルク・シャープ・エンド・ドーム・コーポレイション ベノジアゼピンスピロヒダントインｃｇｒｐ受容体拮抗物質
JO2355B1 (en) 2003-04-15 2006-12-12 ميرك شارب اند دوم كوربوريشن Hereditary calcitonin polypeptide receptor antagonists
US7390798B2 (en) 2004-09-13 2008-06-24 Merck & Co., Inc. Carboxamide spirolactam CGRP receptor antagonists
CA2579847A1 (en) 2004-09-13 2006-03-23 Merck & Co., Inc. Bicyclic anilide spirolactam cgrp receptor antagonists
DE102004063755A1 (de) * 2004-12-29 2006-07-20 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verwendung von CGRP-Antagonisten zur Behandlung und Vorbeugung von Hitzewallungen bei Patienten mit Prostatakrebs
EP1861399B1 (en) 2005-03-14 2011-12-14 Merck Sharp & Dohme Corp. Cgrp receptor antagonists
EA200870521A1 (ru) 2006-05-09 2009-04-28 Мерк Энд Ко., Инк. Замещенные спироциклические антагонисты cgrp-рецепторов
JP5511657B2 (ja) 2007-06-05 2014-06-04 メルク・シャープ・アンド・ドーム・コーポレーション カルボキサミドヘテロ環式ｃｇｒｐ受容体アンタゴニスト
JP5366960B2 (ja) 2007-10-18 2013-12-11 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｃｇｒｐアンタゴニスト
US20120149698A1 (en) 2007-11-22 2012-06-14 Boehringer Ingelheim International Gmbh Nouvel compounds
CA2722536A1 (en) * 2008-02-05 2009-08-13 Merck & Co., Inc. Prodrugs of cgrp receptor antagonist
US8044043B2 (en) 2008-04-11 2011-10-25 Bristol-Myers Squibb Company CGRP receptor antagonists
JP2011516612A (ja) 2008-04-15 2011-05-26 シェーリング コーポレイション 好ましくはポサコナゾールおよびｈｐｍｃａｓを含む固体分散物中の経口用薬学的組成物
WO2010114801A1 (en) * 2009-03-31 2010-10-07 Ligand Pharmaceuticals Inc. Oral formulations of diphenylsulfonamide endothelin and angiotensin ii receptor agonists to treat elevated blood pressure and diabetic nephropathy
EP2438067B1 (de) 2009-06-05 2015-08-26 Boehringer Ingelheim International GmbH Spirolactame als cgrp-antagonisten
NZ605440A (en) * 2010-06-10 2014-05-30 Abbvie Bahamas Ltd Solid compositions comprising an hcv inhibitor
UA113500C2 (xx) * 2010-10-29 2017-02-10 Одержані екструзією розплаву тверді дисперсії, що містять індукуючий апоптоз засіб
AU2011326455A1 (en) 2010-11-12 2013-05-23 Merck Sharp & Dohme Corp. Piperidinone carboxamide indane CGRP receptor antagonists
US8895572B2 (en) 2010-12-22 2014-11-25 Merck Sharp & Dohme Corp. Fused heterocyclic indane carboxamide CGRP receptor antagonists
EP2654423B1 (en) 2010-12-22 2016-12-07 Merck Sharp & Dohme Corp. Fused heterocyclic azaindane carboxamide cgrp receptor antagonists
US8591944B2 (en) * 2011-03-08 2013-11-26 Zalicus Pharmaceuticals Ltd. Solid dispersion formulations and methods of use thereof
WO2012129013A1 (en) 2011-03-18 2012-09-27 Merck Sharp & Dohme Corp. Piperidinone carboxamide spirohydantoin cgrp receptor antagonists
EP2753640B1 (en) 2011-09-08 2016-03-09 Codexis, Inc. Biocatalysts and methods for the synthesis of substituted lactams
CA2852058C (en) 2011-10-14 2021-06-01 Array Biopharma Inc. A solid dispersion of n4-(4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)-3-methylphenyl)-n6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine
BR112014021828B8 (pt) 2012-03-14 2023-04-18 Merck Sharp & Dohme Sal de alcaloide bisquaternário
US9487523B2 (en) 2012-03-14 2016-11-08 Merck Sharp & Dohme Corp. Process for making CGRP receptor antagonists
JP2015514803A (ja) 2012-04-25 2015-05-21 イノーバス ファーマシューティカルズ インコーポレイテッド 増感組成物および使用方法
US9227972B2 (en) 2012-05-09 2016-01-05 Merck Sharp & Dohme Corp. Aliphatic spirolactam CGRP receptor antagonists
WO2013169567A1 (en) 2012-05-09 2013-11-14 Merck Sharp & Dohme Corp. Spirolactam cgrp receptor antagonists
WO2013169563A1 (en) 2012-05-09 2013-11-14 Merck Sharp & Dohme Corp. Pyridine cgrp receptor antagonists
US9174989B2 (en) 2012-05-09 2015-11-03 Merck Sharp & Dohme Corp. Process for making CGRP receptor antagonists
SG10201707528WA (en) 2013-03-15 2017-10-30 Tonix Pharmaceuticals Inc Eutectic formulations of cyclobenzaprine hydrochloride and amitriptyline hydrochloride
EP3915561A1 (en) 2013-09-16 2021-12-01 Merck Sharp & Dohme Corp. Formulations for cgrp receptor antagonists
KR20220136460A (ko) 2014-02-05 2022-10-07 머크 샤프 앤드 돔 엘엘씨 Cgrp-활성 화합물에 대한 정제 제제
EP3102188A4 (en) 2014-02-05 2017-07-12 Merck Sharp & Dohme Corp. Novel disintegration systems for pharmaceutical dosage forms
CN106456662A (zh) 2014-02-24 2017-02-22 奥利金制药公司 口服给药的戊聚糖多硫酸盐的组合物及其使用方法
LT3182975T (lt) 2014-08-22 2025-11-25 Tabletės su didele rukaparibo doze
EA201791662A1 (ru) 2015-01-23 2017-12-29 Грюненталь Гмбх Цебранопадол для лечения от боли субъектов с нарушенной печеночной и/или нарушенной почечной функцией
KR20180058777A (ko) 2015-09-24 2018-06-01 테바 파마슈티컬스 인터내셔널 게엠베하 (지속성) 외상후 두통의 예방, 치료 및 감소
US20180092899A1 (en) 2016-09-30 2018-04-05 Merck Sharp & Dohme Corp. Method of treating acute migraine with cgrp-active compound
EP3589317A1 (en) 2017-03-02 2020-01-08 Beth Israel Deaconess Medical Center, Inc. Selecting headache patients responsive to antibodies directed against calcitonin gene related peptide
TWI754772B (zh) 2017-09-06 2022-02-11 美商美國禮來大藥廠 用於治療偏頭痛之拉米迪坦(lasmiditan)與cgrp拮抗劑之組合療法
US20190135927A1 (en) 2017-09-29 2019-05-09 Bhl Patent Holdings, Llc Migraine, headache, chronic pain treatment, and prophylaxis options
US20190374520A1 (en) 2018-06-08 2019-12-12 Allergan Pharmaceuticals International Limited Treatment of migraine
US20190374518A1 (en) 2018-06-08 2019-12-12 Allergan Pharmaceuticals International Limited Treatment of migraine
TWI826514B (zh) 2018-09-04 2023-12-21 美商美國禮來大藥廠 用於預防偏頭痛之拉米迪坦(lasmiditan)長期夜間投藥
AU2020259461A1 (en) 2019-04-18 2021-11-11 Allergan Sales, Llc CGRP antagonists for the treatment of medication overuse headache, post-traumatic headache, post-concussion syndrome and vertigo
EP4034156A4 (en) 2019-09-25 2024-01-24 Allergan Pharmaceuticals International Limited COMBINATION THERAPY WITH CGRP ANTAGONISTS
AU2021319090A1 (en) 2020-07-29 2023-03-02 Allergan Pharmaceuticals International Limited Treatment of migraine
WO2022140537A1 (en) 2020-12-22 2022-06-30 Allergan Pharmaceuticals International Limited Treatment of migraine
WO2023049920A1 (en) 2021-09-27 2023-03-30 Allergan Pharmaceuticals International Limited Combination comprising atogepant for treating migraine

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040076668A1 (en) * 2002-07-03 2004-04-22 Pfizer Inc. Controlled-release pharmaceutical formulations
CN101378731A (zh) * 2006-02-09 2009-03-04 默克公司 Cetp抑制剂的聚合物制剂
CN103328478A (zh) * 2010-11-12 2013-09-25 默沙东公司 哌啶酮羧酰胺氮杂茚满cgrp受体拮抗剂

Also Published As

Publication number Publication date
AU2021245229A1 (en) 2021-11-04
CA2937315A1 (en) 2015-08-13
US20160346214A1 (en) 2016-12-01
JP6491669B2 (ja) 2019-03-27
SA516371613B1 (ar) 2021-06-19
HK1232218A1 (zh) 2018-01-05
AU2025220825A1 (en) 2025-09-11
KR20220136460A (ko) 2022-10-07
KR102448369B1 (ko) 2022-09-28
MX2021006790A (es) 2021-07-15
JP6666490B2 (ja) 2020-03-13
US20210085612A1 (en) 2021-03-25
WO2015119848A1 (en) 2015-08-13
US10117836B2 (en) 2018-11-06
US20190209478A1 (en) 2019-07-11
MX2016010169A (es) 2016-10-07
KR20160113296A (ko) 2016-09-28
JP2017505306A (ja) 2017-02-16
AU2023258317A1 (en) 2023-11-16
AU2019226239A1 (en) 2019-09-26
MX383378B (es) 2025-03-13
BR112016017999A2 (enExample) 2017-08-08
EP3102564A1 (en) 2016-12-14
IL246828A0 (en) 2016-08-31
AU2015214502B2 (en) 2019-06-06
RU2696578C1 (ru) 2019-08-05
EP3102564A4 (en) 2017-10-18
AU2019226239B2 (en) 2021-07-08
RU2019123406A (ru) 2019-10-03
CN112022818A (zh) 2020-12-04
IL246828B (en) 2019-05-30
CN105960397A (zh) 2016-09-21
US11925709B2 (en) 2024-03-12
KR20230107902A (ko) 2023-07-18
JP2019108366A (ja) 2019-07-04
BR112016017999A8 (pt) 2023-04-11
AU2015214502A1 (en) 2016-07-21
US20230248655A1 (en) 2023-08-10

Similar Documents

Publication Publication Date Title
CN105960397B (zh) Cgrp-活性化合物的片剂制剂
US20130303630A1 (en) Thermo-Kinetic Mixing for Pharmaceutical Applications
US20100143459A1 (en) Pharmaceutical dosage form for oral administration of tyrosine kinase inhibitor
EP3313187B1 (en) Sustained release formulation and tablets prepared therefrom
US12168004B2 (en) Treatment of migraine
US20240180883A1 (en) Treatment of migraine
US20240390285A1 (en) High-dose compressible dosage forms manufactured by simultaneous melt-coating and melt-granulation of active pharmaceutical ingredients
EP4499038B1 (en) Solid composition comprising solubilised bradykinin b2-receptor antagonists
BR112016017999B1 (pt) Comprimido, e, formulação adequada para prensar em um comprimido
WO2024023173A1 (en) Solid pharmaceutical dosage form comprising a bcs class ii drug and a method for producing the same
Williams III et al. Thermo-kinetic mixing for pharmaceutical applications

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant
TR01 Transfer of patent right

Effective date of registration: 20221110

Address after: new jersey

Patentee after: MERCK SHARP & DOHME B.V.

Address before: new jersey

Patentee before: MERCK SHARP & DOHME Corp.

TR01 Transfer of patent right